Progenity, Inc. (PROG)
| Market Cap | 174.23M |
| Revenue (ttm) | 82.01M |
| Net Income (ttm) | -207.91M |
| Shares Out | 57.49M |
| EPS (ttm) | -5.12 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | August 3 |
| Last Price | $2.00 |
| Previous Close | $2.10 |
| Change ($) | -0.10 |
| Change (%) | -4.76% |
| Day's Open | 2.05 |
| Day's Range | 1.97 - 2.06 |
| Day's Volume | 801,269 |
| 52-Week Range | 1.97 - 10.27 |
The company's Preecludia™ test performed strongly in a broad, intended-use population The company's Preecludia™ test performed strongly in a broad, intended-use population
SAN DIEGO, June 30, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced the appointment of Surbhi Sarna to its board of directors effective July 1, 20...
SAN DIEGO, June 17, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced the formation of its Inflammatory Bowel Disease Clinical Advisory Board....
Investors need to pay close attention to Progenity (PROG) stock based on the movements in the options market lately.
SAN DIEGO, June 15, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced that Harry Stylli, PhD, CEO, chairman of the board, and co-founder of Pr...
Looking for penny stocks under $5? Check these 3 out The post Hot Penny Stocks to Buy Under $5?
Women's health diagnostic firm, Progenity Inc (NASDAQ: PROG), will close its genetics laboratory as part of a strategic transformation that emphasizes its drug delivery technologies and therapeutics. Cl...
Progenity Inc (NASDAQ: PROG) has announced results from a preclinical study evaluating the delivery of PGN-001 (adalimumab liquid formulation) drug substance directly to the colon in an animal model of ...
Preclinical study shows therapeutic effect of locally delivered PGN-001 (adalimumab) drug substance Preclinical study shows therapeutic effect of locally delivered PGN-001 (adalimumab) drug substance
SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced the appointment of Sean Lavin, M.D. as Vice President, Business Developme...
Two Abstracts Support Company's Targeted Therapeutics Program including the Drug Delivery System Two Abstracts Support Company's Targeted Therapeutics Program including the Drug Delivery System
Provides educational resources for both patients and healthcare providers Provides educational resources for both patients and healthcare providers
Reports revenues of $24.5 million in the first quarter of 2021, up 72% from prior quarter
Studies show location accuracy and tolerability of the novel oral Drug Delivery System (DDS) and point to a materially enhanced therapeutic/safety index for PGN-600 Studies show location accuracy and to...
SAN DIEGO, May 11, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing products,...
SAN DIEGO, May 06, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing produc...
Pre-validation study demonstrates commercial laboratory systems readiness; data show strong performance consistent with verification study Pre-validation study demonstrates commercial laboratory systems...
Progenity survey shows more women know their baby's “fruit size” than the key indicator of a common pregnancy complication
Data demonstrate strong sensitivity and negative predictive value (NPV) Data demonstrate strong sensitivity and negative predictive value (NPV)
SAN DIEGO, April 26, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing prod...
SAN DIEGO, April 08, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing product...
SAN DIEGO, April 06, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing product...
SAN DIEGO, March 27, 2021 /PRNewswire/ -- Johnson Fistel, LLP is investigating potential claims on behalf of Progenity, Inc. (NASDAQ: PROG) against certain of its officers and directors. In June 2020, ...
Progenity Provides Corporate Updates and Reports Fourth Quarter and Full-Year 2020 Financial Results
Reports approximately 82,000 tests in the fourth quarter of 2020
New York, New York--(Newsfile Corp. - March 14, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Progenity, Inc. ("Silk Road" or the "Company") (NASDAQ: PROG). Such investors are ...
Progenity to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update
SAN DIEGO, March 12, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing prod...
NEW YORK, March 12, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Progenity, Inc. ("Silk Road" or the "Company") (NASDAQ: PROG). Such investors are advised to co...
New York, New York--(Newsfile Corp. - March 7, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Progenity, Inc. ("Silk Road" or the "Company") (NASDAQ: PROG). Such investors are a...
NEW YORK, March 3, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Progenity, Inc. ("Silk Road" or the "Company") (NASDAQ: PROG). Such investors are advised to conta...
SAN DIEGO, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular...
New York, New York--(Newsfile Corp. - February 22, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Progenity, Inc. (NASDAQ: PROG) ("Silk Road" or the "Company"). Such investors a...
SAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing products...
Progenity applauds focus on preeclampsia biomarkers as it prepares for the launch of the Preecludia™ test Progenity applauds focus on preeclampsia biomarkers as it prepares for the launch of the Preeclu...
SAN DIEGO, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing produ...
Progenity's (NASDAQ:PROG) stock has been falling Monday, down 6.19% to a price of $5.9. Monday the stock has been traded at a volume of 209.31 thousand, about 29.44% of its recent 30-day volume average ...
The company celebrates its ten-year anniversary and looks toward future innovations The company celebrates its ten-year anniversary and looks toward future innovations
Total 2021 revenue expected to grow by up to 30% 1 , reaching a range of $130 to $145 million
SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing produ...
SAN DIEGO, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing produ...
Adam Johnson of BullseyeBrief.com presented Tuesday at the Benzinga Global Small Cap Conference, discussing his fund of small-cap stock picks on Bullseye Brief, where subscribers can track his trades an...
SAN DIEGO, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing produ...
SAN DIEGO, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular...
SAN DIEGO, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG) today announced the pricing of its offering of $75.0 million aggregate principal amount of 7.25% convertible senior notes due ...
SAN DIEGO, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular...
SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG) today announced its intention to offer, subject to market and other conditions, $75 million aggregate principal amount of conv...
SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular...
High sensitivity and high negative predictive value (NPV) observed for ruling out the risk of preeclampsia High sensitivity and high negative predictive value (NPV) observed for ruling out the risk of p...
SAN DIEGO, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing produ...
About PROG
Progenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. It offers Innatal, a noninvasive prenatal screening test offered to women early in pregnancy to screen for chromosome abnormalities, such as down syndrome, trisomy 18, trisomy 13, and sex chromosome disorders through the analysis of cell-free DNA; Preparent that screens for carrier status of hereditary diseases prior to or early in pregnancy; and Riscover, a hereditary cancer screen that analyzes 31 genes associated wi... [Read more...]
| Industry Biotechnology | IPO Date Jun 19, 2020 |
| CEO Harry Stylli | Employees 637 |
| Stock Exchange NASDAQ | Ticker Symbol PROG |
Financial Performance
In 2020, Progenity's revenue was $74.31 million, a decrease of -48.39% compared to the previous year's $143.99 million. Losses were -$192.53 million, 30.1% more than in 2019.
Analyst Forecasts
According to 5 analysts, the average rating for Progenity stock is "Strong Buy." The 12-month stock price forecast is 4.75, which is an increase of 137.50% from the latest price.